On November 4, 2021 CTI BioPharma Corp. (Nasdaq: CTIC) reported five poster presentations from the Company’s pacritinib program at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, being held virtually and in Atlanta, Georgia, December 11-14, 2021 (Press release, CTI BioPharma, NOV 4, 2021, View Source [SID1234594370]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(PRNewsfoto/CTI BioPharma Corp.)

The details of the poster presentations are as follows:

Abstract Title: A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia
Publication Number: 3639
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. John Mascarenhas

Abstract title: Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia
Publication Number: 3640
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00 p.m.–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. John Mascarenhas

Abstract Title: Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis
Publication Number: 3649
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00 p.m.–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. (Professor) Claire Harrison

Abstract title: The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study
Publication Number: 3628
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00 p.m.–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. Jeanne Palmer

Abstract title: Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis
Publication Number: 3584
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. Jennifer O’Sullivan

The full abstracts can be viewed here.

About Pacritinib

Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1 and CSF1R, but not JAK1. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT.